HC Wainwright & Co. Downgrades Crinetics Pharmaceuticals to Neutral, Raises Price Target to $85

Benzinga Newsdesk www.benzinga.com Negative 81.3%

Neg 81.3% Neu 0% Pos 0%

HC Wainwright & Co. analyst Douglas Tsao downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) from Buy to Neutral and raises the price target from $81 to $85.